Multiple large randomized controlled trials, including EMPA-REG OUTCOME,[50] NVAS,[51] and CLARE-TIMI 58,[52] have confirmed the significant effects of SGLT-2 inhibitors in reducing the risks of cardiovascular death, HF hospitalization, and all-cause mortality. Here, SLC5A2 is linked to hydrops fetalis.